Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients

Yasuyuki Ohta, Toru Yamashita, Emi Nomura, Nozomi Hishikawa, Ken Ikegami, Yosuke Osakada, Namiko Matsumoto, Yuko Kawahara, Taijun Yunoki, Yoshiaki Takahashi, Motonori Takamiya, Koh Tadokoro, Ryo Sasaki, Yumiko Nakano, Keiichiro Tsunoda, Kota Sato, Yosio Omote, Mami Takemoto, Koji Abe

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)


Background: The free radical scavenger edaravone is a proven neuroprotective drug for patients with amyotrophic lateral sclerosis (ALS). Our objective was to evaluate the therapeutic effects of edaravone for oxidative stress and anti-oxidative activity in ALS patients. Methods: Twenty-two ALS patients with a disease duration of 2 years, treated by edaravone, and 25 control participants were evaluated according to their clinical scores, including ALS functional rating scale-revised (ALSFRS-R), and serum and cerebrospinal fluid (CSF) markers of oxidative stress dROM and anti-oxidative activity OXY. Results: Serum and CSF markers of anti-oxidative activity OXY were significantly decreased in ALS patients at pre-treatment compared with controls (##p < .01), which was improved in the course of edaravone treatment. Both serum and CSF OXY were significantly correlated with ALS clinical scores including ALSFRS-R (*p < .05, **p < .01, ***p < .001). Furthermore, serum OXY at pre-treatment was significantly correlated with a change in the ALSFRS-R score in the sixth cycle of edaravone treatment (*p < .05). Conclusions: The present study suggests significant correlations between anti-oxidative activity and ALS clinical severity, and the therapeutic efficacy of edaravone for decreased anti-oxidative activity in ALS.

Original languageEnglish
Article number116906
JournalJournal of the neurological sciences
Publication statusPublished - Aug 15 2020


  • ALS
  • Anti-oxidative activity
  • Edaravone
  • OXY
  • Oxidative stress

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients'. Together they form a unique fingerprint.

Cite this